Page last updated: 2024-12-10

5,6-epoxy-8,11,14-eicosatrienoic acid

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

5,6-epoxy-8,11,14-eicosatrienoic acid: RN given refers to cpd without isomeric designation [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

5,6-EET : An EET obtained by formal epoxidation of the 5,6-double bond of arachidonic acid. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Cross-References

ID SourceID
PubMed CID5283202
CHEMBL ID1893588
CHEBI ID34450
SCHEMBL ID2508938
MeSH IDM0121241

Synonyms (44)

Synonym
5,6-epetre
5,6-epoxy-8,11,14-eicosatrienoic acid
(+/-)5,6-epetre
5,6-epoxy-8z,11z,14z-eicosatrienoic acid
LMFA03080002
5,6-eet
BSPBIO_001447
(8z,11z,14z)-5,6-epoxyicosa-8,11,14-trienoic acid
(8z,11z,14z)-5,6-epoxyeicosa-8,11,14-trienoic acid
NCGC00161265-02
NCGC00161265-01
IDI1_033917
NCGC00161265-03
HMS1989I09
5,6-epoxyeicosatrienoic acid
BML1-D08
HMS1791I09
HMS1361I09
4-[3-[(2z,5z,8z)-tetradeca-2,5,8-trienyl]oxiran-2-yl]butanoic acid
5',6'-epoxyeicosatrienoic acid
81246-84-6
5,6-epoxy-8,11,14-icosatrienoic acid
4-{3-[(2z,5z,8z)-tetradeca-2,5,8-trien-1-yl]oxiran-2-yl}butanoic acid
CHEBI:34450 ,
5,6-epoxy-8z,11z,14z-icosatrienoic acid
(plusmn)5,6-epoxy-8z,11z,14z-eicosatrienoic acid
(plusmn)5,6-epetre
gtpl6304
SCHEMBL2508938
CHEMBL1893588 ,
VBQNSZQZRAGRIX-QNEBEIHSSA-N
5(6)-epoxy-8z,11z,14z-eicosatrienoic acid
5(6)-eet
2-oxiranebutanoic acid, 3-(2z,5z,8z)-2,5,8-tetradecatrien-1-yl-
HMS3402I09
(8z,11z,14z)-5,6-epoxyeicosa-8,11,14-trienoate
(8z,11z,14z)-5,6-epoxyicosa-8,11,14-trienoate
5,6-epoxy-8z,11z,14z-eicosatrienoate
(+/-)5(6)-eet
Q27073967
5(6)-eet-[d11]
(+/-)-5,6-epoxy-8z,11z,14z-eicosatrienoic acid
bdbm50545034
PD046983

Research Excerpts

Dosage Studied

ExcerptRelevanceReference
" Dose-response curves (10(-9) to 10(-6) M) to 5,6-EET, 8,9-EET, 11,12-EET, 14,15-EET, and ACh (10(-9) to 10(-4) M) were evaluated in preconstricted (10(-6) mol/l phenylephrine) mesenteric arteries (<350 microm diameter) in the presence or absence of 1) the cyclooxygenase inhibitor indomethacin (2."( Rat mesenteric arterial dilator response to 11,12-epoxyeicosatrienoic acid is mediated by activating heme oxygenase.
Abraham, NG; Bolognesi, M; Di Pascoli, M; Gatta, A; McGiff, JC; Sacerdoti, D; Schwartzman, ML, 2006
)
0.33
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Roles (1)

RoleDescription
mouse metaboliteAny mammalian metabolite produced during a metabolic reaction in a mouse (Mus musculus).
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (1)

ClassDescription
EETAn icosanoid obtained by formal epoxidation of one of the double bonds of arachidonic acid.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Pathways (50)

PathwayProteinsCompounds
Metabolism14961108
Metabolism of lipids500463
Fatty acid metabolism113203
Arachidonic acid metabolism3682
Synthesis of epoxy (EET) and dihydroxyeicosatrienoic acids (DHET)18
Arachidonic Acid Metabolism2966
Leukotriene C4 Synthesis Deficiency2966
Piroxicam Action Pathway2967
Acetylsalicylic Acid Action Pathway2967
Etodolac Action Pathway2967
Ketoprofen Action Pathway2967
Ibuprofen Action Pathway5076
Rofecoxib Action Pathway2967
Diclofenac Action Pathway2967
Sulindac Action Pathway2967
Celecoxib Action Pathway3573
Ketorolac Action Pathway2967
Suprofen Action Pathway2967
Bromfenac Action Pathway2967
Indomethacin Action Pathway3067
Mefenamic Acid Action Pathway2967
Oxaprozin Action Pathway2967
Nabumetone Action Pathway2967
Naproxen Action Pathway2967
Diflunisal Action Pathway2967
Meloxicam Action Pathway2967
Valdecoxib Action Pathway2967
Antipyrine Action Pathway2967
Antrafenine Action Pathway2967
Carprofen Action Pathway2967
Etoricoxib Action Pathway2967
Fenoprofen Action Pathway2967
Flurbiprofen Action Pathway2967
Magnesium Salicylate Action Pathway2967
Lumiracoxib Action Pathway2967
Lornoxicam Action Pathway2967
Phenylbutazone Action Pathway2967
Nepafenac Action Pathway2967
Trisalicylate-Choline Action Pathway2967
Tolmetin Action Pathway2967
Tiaprofenic Acid Action Pathway2967
Tenoxicam Action Pathway2967
Salsalate Action Pathway2967
Salicylate-Sodium Action Pathway2967
Salicylic Acid Action Pathway2967
Acetaminophen Action Pathway2967
Eicosanoid metabolism via cytochrome P450 monooxygenases pathway113
Arachidonic acid (AA, ARA) oxylipin metabolism076
Eicosanoid metabolism via cytochrome P450 monooxygenases213
Arachidonate epoxygenase / epoxide hydrolase09
Arachidonic acid metabolism via CYP (Cytochromoe P450) pathway014

Protein Targets (2)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
regulator of G-protein signaling 4Homo sapiens (human)Potency37.68580.531815.435837.6858AID504845
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Activation Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Transient receptor potential cation channel subfamily V member 4 Mus musculus (house mouse)EC50 (µMol)0.15000.15001.38006.3000AID1667132
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (4)

Assay IDTitleYearJournalArticle
AID588519A screen for compounds that inhibit viral RNA polymerase binding and polymerization activities2011Antiviral research, Sep, Volume: 91, Issue:3
High-throughput screening identification of poliovirus RNA-dependent RNA polymerase inhibitors.
AID540299A screen for compounds that inhibit the MenB enzyme of Mycobacterium tuberculosis2010Bioorganic & medicinal chemistry letters, Nov-01, Volume: 20, Issue:21
Synthesis and SAR studies of 1,4-benzoxazine MenB inhibitors: novel antibacterial agents against Mycobacterium tuberculosis.
AID1346607Mouse TRPV4 (Transient Receptor Potential channels)2003Nature, Jul-24, Volume: 424, Issue:6947
Anandamide and arachidonic acid use epoxyeicosatrienoic acids to activate TRPV4 channels.
AID1667132Agonist activity at mouse TRPV42020Bioorganic & medicinal chemistry letters, 04-15, Volume: 30, Issue:8
Recent advances in TRPV4 agonists and antagonists.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (134)

TimeframeStudies, This Drug (%)All Drugs %
pre-199014 (10.45)18.7374
1990's49 (36.57)18.2507
2000's48 (35.82)29.6817
2010's19 (14.18)24.3611
2020's4 (2.99)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 9.87

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index9.87 (24.57)
Research Supply Index4.91 (2.92)
Research Growth Index4.78 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (9.87)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials1 (0.75%)5.53%
Reviews8 (5.97%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other125 (93.28%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]